Cargando…

Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity

BACKGROUND: Breast cancer cells frequently metastasize to the skeleton and induce extensive bone destruction. Cancer cells produce proteinases, including matrix metalloproteinases (MMPs) and the plasminogen activator system (PAS) which promote invasion of extracellular matrices, but whether these pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Morgan, Hayley, Hill, Peter A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC548674/
https://www.ncbi.nlm.nih.gov/pubmed/15701164
http://dx.doi.org/10.1186/1475-2867-5-1
_version_ 1782122366537564160
author Morgan, Hayley
Hill, Peter A
author_facet Morgan, Hayley
Hill, Peter A
author_sort Morgan, Hayley
collection PubMed
description BACKGROUND: Breast cancer cells frequently metastasize to the skeleton and induce extensive bone destruction. Cancer cells produce proteinases, including matrix metalloproteinases (MMPs) and the plasminogen activator system (PAS) which promote invasion of extracellular matrices, but whether these proteinases degrade bone matrix is unclear. To characterize the role that breast cancer cell proteinases play in bone degradation we compared the effects of three human breast cancer cell lines, MDA-MB-231, ZR-75-1 and MCF-7 with those of a normal breast epithelial cell line, HME. The cell lines were cultured atop radiolabelled matrices of either mineralized or non-mineralized bone or type I collagen, the principal organic constituent of bone. RESULTS: The 3 breast cancer cell lines all produced significant degradation of the 3 collagenous extracellular matrices (ECMs) whilst the normal breast cell line was without effect. Breast cancer cells displayed an absolute requirement for serum to dissolve collagen. Degradation of collagen was abolished in plasminogen-depleted serum and could be restored by the addition of exogenous plasminogen. Localization of plasmin activity to the cell surface was critical for the degradation process as aprotinin, but not α(2 )antiplasmin, prevented collagen dissolution. During ECM degradation breast cancer cell lines expressed urokinase-type plasminogen activator (u-PA) and uPA receptor, and MMPs-1, -3, -9,-13, and -14. The normal breast epithelial cell line expressed low levels of MMPs-1, and -3, uPA and uPA receptor. Inhibitors of both the PAS (aprotinin and PA inhibitor-1) and MMPs (CT1166 and tisue inhibitor of metalloproteinase) blocked collagen degradation, demonstrating the requirement of both plasminogen activation and MMP activity for degradation. The activation of MMP-13 in human breast cancer cells was prevented by plasminogen activator inhibitor-1 but not by tissue inhibitor of metalloproteinase-1, suggesting that plasmin activates MMP-13 directly. CONCLUSIONS: These data demonstrate that breast cancer cells dissolve type I collagen and that there is an absolute requirement for plasminogen activation and MMP activity in the degradation process.
format Text
id pubmed-548674
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-5486742005-02-13 Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity Morgan, Hayley Hill, Peter A Cancer Cell Int Primary Research BACKGROUND: Breast cancer cells frequently metastasize to the skeleton and induce extensive bone destruction. Cancer cells produce proteinases, including matrix metalloproteinases (MMPs) and the plasminogen activator system (PAS) which promote invasion of extracellular matrices, but whether these proteinases degrade bone matrix is unclear. To characterize the role that breast cancer cell proteinases play in bone degradation we compared the effects of three human breast cancer cell lines, MDA-MB-231, ZR-75-1 and MCF-7 with those of a normal breast epithelial cell line, HME. The cell lines were cultured atop radiolabelled matrices of either mineralized or non-mineralized bone or type I collagen, the principal organic constituent of bone. RESULTS: The 3 breast cancer cell lines all produced significant degradation of the 3 collagenous extracellular matrices (ECMs) whilst the normal breast cell line was without effect. Breast cancer cells displayed an absolute requirement for serum to dissolve collagen. Degradation of collagen was abolished in plasminogen-depleted serum and could be restored by the addition of exogenous plasminogen. Localization of plasmin activity to the cell surface was critical for the degradation process as aprotinin, but not α(2 )antiplasmin, prevented collagen dissolution. During ECM degradation breast cancer cell lines expressed urokinase-type plasminogen activator (u-PA) and uPA receptor, and MMPs-1, -3, -9,-13, and -14. The normal breast epithelial cell line expressed low levels of MMPs-1, and -3, uPA and uPA receptor. Inhibitors of both the PAS (aprotinin and PA inhibitor-1) and MMPs (CT1166 and tisue inhibitor of metalloproteinase) blocked collagen degradation, demonstrating the requirement of both plasminogen activation and MMP activity for degradation. The activation of MMP-13 in human breast cancer cells was prevented by plasminogen activator inhibitor-1 but not by tissue inhibitor of metalloproteinase-1, suggesting that plasmin activates MMP-13 directly. CONCLUSIONS: These data demonstrate that breast cancer cells dissolve type I collagen and that there is an absolute requirement for plasminogen activation and MMP activity in the degradation process. BioMed Central 2005-02-08 /pmc/articles/PMC548674/ /pubmed/15701164 http://dx.doi.org/10.1186/1475-2867-5-1 Text en Copyright © 2005 Morgan and Hill; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Primary Research
Morgan, Hayley
Hill, Peter A
Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity
title Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity
title_full Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity
title_fullStr Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity
title_full_unstemmed Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity
title_short Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity
title_sort human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity
topic Primary Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC548674/
https://www.ncbi.nlm.nih.gov/pubmed/15701164
http://dx.doi.org/10.1186/1475-2867-5-1
work_keys_str_mv AT morganhayley humanbreastcancercellmediatedbonecollagendegradationrequiresplasminogenactivationandmatrixmetalloproteinaseactivity
AT hillpetera humanbreastcancercellmediatedbonecollagendegradationrequiresplasminogenactivationandmatrixmetalloproteinaseactivity